Login Register Cart 0
Generic placeholder image

Current Vascular Pharmacology

Editor-in-Chief

ISSN (Print): 1570-1611
ISSN (Online): 1875-6212

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Editorial

Exploring the High Burden of Cardiovascular Disease Among Patients with End-Stage Renal Disease

Author(s): Vassilios Liakopoulos* and Panagiotis I. Georgianos

Volume 19, Issue 1, 2021

Published on: 28 October, 2020

Page: [1 - 3] Pages: 3

DOI: 10.2174/157016111901201028093749

Next »
[1]
Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-305.
[http://dx.doi.org/10.1056/NEJMoa041031] [PMID: 15385656]
[2]
Matsushita K, van, d,V, Astor BC,et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010; 375: 2073-81.
[http://dx.doi.org/10.1016/S0140-6736(10)60674-5] [PMID: 20483451]
[3]
Debella YT, Giduma HD, Light RP, Agarwal R. Chronic kidney disease as a coronary disease equivalent--a comparison with diabetes over a decade. Clin J Am Soc Nephrol 2011; 6: 1385-92.
[http://dx.doi.org/10.2215/CJN.10271110] [PMID: 21393492]
[4]
Tonelli M, Muntner P, Lloyd A, et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a populationlevel cohort study. Lancet 2012; 380: 807-14.
[http://dx.doi.org/10.1016/S0140-6736(12)60572-8]
[5]
Sarnak MJ, Amann K, Bangalore S, et al. Chronic kidney disease and coronary artery disease: JACC state-of-the-Art review. J Am Coll Cardiol 2019; 74: 1823-38.
[http://dx.doi.org/10.1016/j.jacc.2019.08.1017] [PMID: 31582143]
[6]
Pippias M, Stel VS, Abad Diez JM, et al. Renal replacement therapy in Europe: a summary of the 2012 ERA-EDTA Registry Annual Report. Clin Kidney J 2015; 8: 248-61.
[http://dx.doi.org/10.1093/ckj/sfv014] [PMID: 26034584]
[7]
Nordio M, Limido A, Maggiore U, Nichelatti M, Postorino M, Quintaliani G. Survival in patients treated by long-term dialysis compared with the general population. Am J Kidney Dis 2012; 59: 819-28.
[http://dx.doi.org/10.1053/j.ajkd.2011.12.023]
[8]
van Walraven C, Manuel DG, Knoll G. Survival trends in ESRD patients compared with the general population in the United States. Am J Kidney Dis 2014; 63: 491-9.
[http://dx.doi.org/10.1053/j.ajkd.2013.09.011]
[9]
Georgianos PI, Agarwal R. Epidemiology, diagnosis and management of hypertension among patients on chronic dialysis. Nat Rev Nephrol 2016; 12: 636-47.
[http://dx.doi.org/10.1038/nrneph.2016.129] [PMID: 27573731]
[10]
Covic A, Siriopol D. Assessment and management of volume overload among patients on chronic dialysis. Curr Vasc Pharmacol 2021; 19(1): 34-44.
[http://dx.doi.org/10.2174/1570161118666200225093827] [PMID: 32096744]
[11]
Georgianos P, Agarwal R. Antihypertensive therapy in patients receiving maintenance hemodialysis: a narrative review of the available clinical-trial evidence. Curr Vasc Pharmacol 2021; 19(1): 12-20.
[http://dx.doi.org/10.2174/1570161118666200317151000] [PMID: 32183679]
[12]
Georgianos PI, Sarafidis PA, Sinha AD, Agarwal R. Adverse effects of conventional thrice-weekly hemodialysis: is it time to avoid 3-day interdialytic intervals? Am J Nephrol 2015; 41: 400-8.
[http://dx.doi.org/10.1159/000435842] [PMID: 26139107]
[13]
Roumeliotis A, Roumeliotis S, Chan C, Pierratos A. Cardiovascular benefits of extended-time nocturnal hemodialysis. Curr Vasc Pharmacol 2021; 19(1): 21-33.
[http://dx.doi.org/10.2174/1570161118666200401112106] [PMID: 32234001]
[14]
Briet M, Boutouyrie P, Laurent S, London GM. Arterial stiffness and pulse pressure in CKD and ESRD. Kidney Int 2012; 82: 388-400.
[http://dx.doi.org/10.1038/ki.2012.131] [PMID: 22534962]
[15]
Roumeliotis S, Roumeliotis A, Gorny X, Mertens P. Could antioxidant supplementation delay progression of cardiovascular disease in end-stage renal disease patients? Curr Vasc Pharmacol 2021; 19(1): 41-54.
[http://dx.doi.org/10.2174/1570161118666200317151553] [PMID: 32183680]
[16]
Dounousi E, Duni A, Naka K, Vartholomatos G, Zoccali C. The Innate immune system and cardiovascular disease in ESKD: monocytes and natural killer cells. Curr Vasc Pharmacol 2021; 19(1): 63-76.
[http://dx.doi.org/10.2174/1570161118666200628024027] [PMID: 32600233]
[17]
Memmos E, Papagianni A. New insights into the role of FGF-23 and Klotho in cardiovascular disease in chronic kidney disease patients. Curr Vasc Pharmacol 2021; 19(1): 55-62.
[http://dx.doi.org/10.2174/1570161118666200420102100] [PMID: 32310050]
[18]
Roumeliotis S, Roumeliotis A, Dounousi E, Eleftheriadis T, Liakopoulos V. Vitamin K for the treatment of cardiovascular disease in End-Stage Renal Disease patients: is there hope? Curr Vasc Pharmacol 2021; 19(1): 77-90.
[http://dx.doi.org/10.2174/1570161118666200320111745] [PMID: 32196451]
[19]
Laurent S, Cockcroft J, Van BL, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006; 27: 2588-605.
[http://dx.doi.org/10.1093/eurheartj/ehl254] [PMID: 17000623]
[20]
Georgianos PI, Vaios V, Eleftheriadis T, Zebekakis PE, Liakopoulos V. Pulse wave velocity assessment for cardiovascular risk prognostication in ESKD: weighting recent evidence. Curr Vasc Pharmacol 2021; 19(1): 4-11.
[http://dx.doi.org/10.2174/1570161118666200403142451] [PMID: 32242783]

Rights & Permissions Print Cite
Article Metrics
5
© 2024 Bentham Science Publishers | Privacy Policy